BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
Cancer Pain - Pipeline Review, H2 2016

Cancer Pain - Pipeline Review, H2 2016

Summary


Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 5, 3, 19, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Cancer Pain.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and

https://www.biopartfolio.co.uk/product/20610
pdf@biopartfolio.co.uk to order
universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct
Reference : GMDHC8691IDB
Number of Pages : 157
Report Format : PDF
Publisher Information :

https://www.bioportfolio.co.uk/product/20610
pdb@bioportfolio.co.uk to order
Table Of Contents for Cancer Pain - Pipeline Review, H2 2016 [Published by Global Markets Direct]

- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report
  - Coverage
  - Cancer Pain Overview
  - Therapeutics Development
  - Pipeline Products for Cancer Pain - Overview
  - Comparative Analysis
  - Cancer Pain - Therapeutics under Development by Companies
  - Cancer Pain - Therapeutics under Investigation by Universities/Institutes
  - Cancer Pain - Pipeline Products Glance
    - Late Stage Products
    - Clinical Stage Products
    - Early Stage Products
    - Unknown Stage Products
  - Cancer Pain - Products under Development by Companies
  - Cancer Pain - Products under Investigation by Universities/Institutes
  - Cancer Pain - Companies Involved in Therapeutics Development
  - Cancer Pain - Therapeutics Assessment
    - Assessment by Monotherapy Products
    - Assessment by Target
    - Assessment by Mechanism of Action
    - Assessment by Route of Administration
    - Assessment by Molecule Type
  - Drug Profiles
    - ANG-2002 - Drug Profile
    - AQU-118 - Drug Profile
    - AZD-8797 - Drug Profile
    - BBI-11008 - Drug Profile
    - buprenorphine hydrochloride - Drug Profile
    - cebranopadol - Drug Profile
    - CPC-111 - Drug Profile
    - crotalphine - Drug Profile
    - CSTI-200 - Drug Profile
    - dexmedetomidine hydrochloride - Drug Profile
    - dronabinol - Drug Profile
    - Drug 1 for Migraine and Cancer Pain - Drug Profile
    - Drug 2 for Migraine and Cancer Pain - Drug Profile
    - Drug 3 for Migraine and Cancer Pain - Drug Profile
    - Drug for Cancer Neuropathic Pain - Drug Profile
    - Drug 85 for Migraine and Cancer Pain - Drug Profile
    - Drug 86fentanyl - Drug Profile
    - Drug 87fentanyl citrate - Drug Profile
    - Drug 88fentanyl citrate - Drug Profile
    - Drug 90fentanyl citrate - Drug Profile
    - Drug 91fentanyl citrate ER - Drug Profile
    - Drug 92gabapentin - Drug Profile
    - Drug 93HP-3150 - Drug Profile
    - Drug 94HS-198 - Drug Profile
    - Drug 95hydroxymorphine hydrochloride - Drug Profile
    - Drug 96HYLP-002 - Drug Profile
    - Drug 97INT-0010 - Drug Profile
    - Drug 98IPP-102199 - Drug Profile
    - Drug 99methadone hydrochloride - Drug Profile
    - Drug 100nabiximols - Drug Profile
    - Drug 101Nervarina - Drug Profile
    - Drug 108PAK-1 - Drug Profile
    - Drug 109Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain - Drug Profile
    - Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile
    - Drug 110Peptide to Target CANP for Cardiovascular and Cancer Pain - Drug Profile
    - Drug 111PL-265 - Drug Profile
    - Drug 112QX-314 - Drug Profile
    - Drug 113RBM-004 - Drug Profile
    - Drug 114RBM-007 - Drug Profile
    - Drug 115resiniferatoxin - Drug Profile
    - Drug 116sarcatinib difumarate - Drug Profile
    - Drug 118small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
    - Drug 120small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
    - Drug 121 small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
    - Drug 122small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile
    - Drug 123tanezumab - Drug Profile
    - Drug 124Tetrodotoxin - Drug Profile
    - Drug 127tilidine hydrochloride - Drug Profile
    - Drug 129U-2902 - Drug Profile
    - Drug 130VBY-825 - Drug Profile
    - Drug 132zucapsaicin - Drug Profile
    - Drug 133ZYN-001 - Drug Profile
    - Drug 135Cancer Pain - Dormant Projects Drug Profile
    - Drug 137Cancer Pain - Discontinued Products
    - Drug 141Cancer Pain - Product Development Milestones
    - 142Featured News & Press Releases
  - Appendix

© BioPortfolio Limited - 2019

https://www.bioprotfolio.co.uk/product/20610

pdb@bioprotfolio.co.uk to order
How to Buy...

Cancer Pain - Pipeline Review, H2 2016 [Published by Global Markets Direct]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/20610

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk
or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ..............................................................................................................................
Job Title: ......................................................................................................................................
Your Email: .................................................................................................................................
Your Contact Phone: .....................................................................................................................
Company Name: ...........................................................................................................................
Address: .........................................................................................................................................
Post/Zip Code: ..............................................................................................................................
Country: ...........................................................................................................................................
P.O. Number: .................................................................................................................................
Any Other Instructions: ..................................................................................................................

Pricing Options: (please tick one)
O $2000 | Single User Price
O $4000 | Site License Price
O $6000 | Enterprise License Price

Payment Options: (please tick one)
O Online Credit Card (we will email you the invoice with a payment link)
O Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ................................................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.